Recent studies have shown that post-transplant survival in TP53-mutated MDS/AML is highly dependent on patient fitness and disease status, with poor outcomes in those with high comorbidity, poor performance, or residual disease at transplant (31, 32). The gene discussed is TP53; the disease is acute myeloid leukemia.